Biometry

myBiometry remotely monitors and manages chronic-condition patients using software and biomarker data from proprietary sensors. Its initial focus is asthma, using Fractional Exhaled Nitric Oxide (FeNO) to assess medication adherence, efficacy, and attack risk.

Biometry Inc. (myBiometry), a firm specializing in asthma and COPD diagnostics and remote monitoring, secures $5 million in an oversubscribed seed round. Dexcom Ventures leads the funding, joined by CareSource Indiana and Elevate Ventures. The capital will advance myBiometry’s development of respiratory health monitoring solutions.

Jan 2025Boston Harbor AngelsNews article

myBiometry secures a $5 million oversubscribed seed funding round led by Dexcom Ventures. The company develops diagnostics and remote monitoring solutions for asthma and COPD patients. Investors show strong demand for its health-tech innovations.

Jan 2025Medical Product OutsourcingNews article

MyBiometry, a Massachusetts-based health tech firm, raises **$5 million in seed funding** after winning the Rally IN-Prize pitch contest. The company also hires its first employees in Indiana while awaiting regulatory approval for its **asthma diagnostic test**. MyBiometry develops medical devices to improve respiratory health monitoring.

Nov 2024Indianapolis Business JournalNews article

Boston-based **myBiometry** raises **$5 million** to advance regulatory approval for a medical device targeting **asthma and COPD patients**. The funding supports development of a solution designed to monitor or manage respiratory conditions. The company focuses on improving outcomes through wearable or portable technology.

Nov 2024citybizNews article